Sorry, looks like we don't have enough of this product.
The honest, evidence-based UK guide to ashwagandha for cortisol reduction. 16 randomised controlled trials, four meta-analyses, the first 12-month safety dataset, and the 2025 meta-analytic finding most supplement brands do not publish. KSM-66® dosing, the 1,500mg label trap, an 8-week timeline, and the Elysium 6-Stage Cortisol Reset Protocol.
A rigorous review of 16 randomised controlled trials, four meta-analyses, and the first 12-month safety dataset — including the honest findings most UK supplement brands will not publish.
The bottom line: Ashwagandha — specifically KSM-66® root extract standardised to ≥5% withanolides — is the most clinically validated botanical intervention for elevated cortisol. Across 15 RCTs and 873 participants in the most recent meta-analysis (Bachour et al., 2025, BJPsych Open), it significantly reduces serum cortisol. The clinical dose is 300–600mg daily of a standardised extract. Effects on measurable cortisol appear within 8 weeks.
The honest nuance: A 2025 meta-analysis found significant cortisol reduction but no significant improvement in perceived stress scores (Albalawi, 2025). What this means: ashwagandha lowers the hormone — but managing chronic stress requires addressing the structural sources of stress alongside the hormonal response. We explain the clinical context in full below.
The UK label problem: Most UK ashwagandha products sell 1,500mg of root powder — which contains roughly 15–75mg of actual withanolides depending on standardisation. At the clinical dose (≥5% withanolides from a genuine root extract), 600mg delivers ≥30mg of guaranteed withanolides. The label "1,500mg ashwagandha" is not the same as 600mg KSM-66®. This distinction is never explained on packaging — it is the most important purchasing decision in the category.
Cortisol is not a villain. It is one of the most important hormones the human body produces — a glucocorticoid secreted by the adrenal cortex that governs energy mobilisation, immune function, blood pressure regulation, glucose metabolism, and the acute stress response. In evolutionary terms, cortisol exists to help a person respond to threat. Released in a surge, it sharpens focus, redirects blood flow to muscles, raises blood glucose for fuel, dampens inflammation, and suppresses non-essential functions such as digestion, reproduction, and immunity. Then, critically, it falls away.
The problem in contemporary life is that cortisol rarely falls away. The stressors of modern existence — overloaded work schedules, financial pressure, poor sleep, dietary dysregulation, blue light at night, digital overstimulation, and the persistent low-grade alertness that comes with always being reachable — are not resolved in minutes. They are continuous. And when the cortisol response designed for acute emergencies runs at a low-grade level day after day, the downstream consequences accumulate in ways that most people recognise as symptoms long before they identify the underlying mechanism.
Chronic cortisol elevation is associated with disrupted sleep architecture — specifically reduced slow-wave sleep and REM duration, leaving people feeling unrefreshed regardless of hours slept. It is associated with suppressed immune function, increased systemic inflammatory markers, impaired memory consolidation through hippocampal effects, metabolic dysregulation including increased visceral fat deposition and insulin resistance, reduced testosterone and reproductive hormone function, accelerated skin ageing through collagen degradation, and the persistent subjective experience of being simultaneously exhausted and unable to wind down.
For a deeper exploration of how cortisol drives sleep disruption, see our Cortisol and Sleep guide. For the broader systems view of HPA axis dysfunction, our HPA Axis and Stress reference provides the underlying physiology. For the magnesium-cortisol connection — which we return to in the stacking section — see Magnesium and Cortisol.
One symptom presentation deserves particular attention because it is so common in the UK adult population and so often misunderstood: the wired-and-tired state. The experience is paradoxical — exhausted throughout the day, unable to focus, energy crashes in mid-afternoon, then a strange second wind in the evening, lying in bed with the mind racing at midnight despite physical fatigue. Sleep, when it comes, is shallow and broken. Morning brings no relief.
This presentation is a near-textbook signature of HPA axis dysregulation. The hypothalamic-pituitary-adrenal axis, which governs cortisol output, has lost its normal diurnal rhythm. In a healthy pattern, cortisol peaks within 30–45 minutes of waking (the cortisol awakening response, or CAR) and gradually declines through the day, reaching its lowest point around midnight before beginning to rise again before dawn. In chronically stressed individuals, the pattern flattens or inverts: cortisol remains elevated through the evening, disrupting sleep onset, and is blunted in the morning, impairing the alertness and focus that should characterise the first hours of the day.
Understanding this mechanism is essential to understanding why ashwagandha works for so many people — and why it is a more mechanistically rational intervention than most consumers realise when they first encounter the supplement category. It does not act as a sedative or as a stimulant. It acts at the level of the hormonal cascade that has become dysregulated, restoring the normal rhythm rather than overriding it. This distinguishes ashwagandha from interventions like sleeping tablets or caffeine, which address symptoms without addressing the underlying signalling problem.
If your stress profile leans more toward acute anxiety and physical agitation rather than the wired-and-tired pattern specifically, you may also find our Ashwagandha for Anxiety guide useful. For the related question of how long the cortisol effect typically takes to produce subjective improvement, see How Long Does Ashwagandha Take to Work.
Ashwagandha (Withania somnifera) is classified as an adaptogen — a botanical agent that supports the body's physiological capacity to respond to stress without disrupting baseline function. Unlike pharmacological anxiolytics or sedatives, adaptogens do not override the stress response; they modulate its amplitude and duration, restoring normal regulatory function rather than suppressing it entirely. The broader category of adaptogens is covered in our Adaptogens UK reference.
The active constituents responsible for ashwagandha's cortisol-modulating effects are withanolides — a class of steroidal lactones found primarily in the root of the plant. Of particular relevance are withaferin A and withanolide D, which have been shown in preclinical models to interact with glucocorticoid receptors and modulate the downstream signalling cascade of the HPA axis (Wiciński et al., 2023). The specific mechanism involves reduced sensitivity of the hypothalamus to stress signals, resulting in attenuated CRH (corticotropin-releasing hormone) release, which in turn reduces ACTH (adrenocorticotropic hormone) secretion from the pituitary, which in turn reduces cortisol output from the adrenal cortex. Withanolides cross the blood-brain barrier and act centrally — distinguishing the mechanism from peripheral cortisol blockers. For a deeper exploration of the active compounds themselves, see our Ashwagandha Withanolides reference.
This upstream action is what distinguishes ashwagandha from interventions that simply blunt cortisol output at the adrenal level. Because the HPA axis is a feedback loop — cortisol itself signals the hypothalamus to reduce CRH production — supplementation with ashwagandha supports rather than overrides the body's own regulatory mechanism. This is clinically meaningful: it explains why ashwagandha does not suppress cortisol to pathologically low levels at standard doses, and why the 12-month safety data (Salve et al., 2025) shows no evidence of adrenal suppression in healthy adults using clinical doses (300–600mg/day of standardised extract).
There is one important caveat worth naming directly, because it is almost never mentioned in UK supplement content: a 2026 case report described a 55-year-old woman who developed confirmed adrenal insufficiency after taking approximately 950mg of ashwagandha daily for one year, with HPA axis suppression persisting six months after discontinuation. This is a single case report, not a trial finding, and should be contextualised accordingly. But it reinforces the importance of staying within the clinically validated dose range and not assuming that higher doses produce proportionally greater benefit. The principle "more is better" does not apply to HPA modulators.
The clinical dose range for cortisol modulation is 300–600mg/day of a standardised root extract (≥5% withanolides by HPLC verification). This is the range used across the RCT literature. Doses significantly above 600mg/day have not been shown to produce greater cortisol reduction in healthy adults and carry the theoretical risk of HPA axis over-suppression in vulnerable individuals.
The evidence base for ashwagandha and cortisol is now substantial. What follows is a structured review of the key trials and meta-analyses — named, with doses, sample sizes, and findings, because that is the standard this article holds itself to. For broader context on Withania somnifera, see our Ashwagandha and Stress reference and the Best Ashwagandha UK buying guide.
The study that established the evidence foundation for KSM-66® in stress and cortisol management. A double-blind, randomised, placebo-controlled trial in 64 adults with a history of chronic stress, receiving 300mg of KSM-66® twice daily (600mg/day total) or placebo for 60 days. The ashwagandha group demonstrated a 27.9% reduction in serum cortisol compared to 7.9% in the placebo group (p<0.001). Perceived Stress Scale (PSS) scores improved by 44% versus 5.5% in the placebo group. The General Health Questionnaire-28 (GHQ-28) and DASS-21 also showed significant improvement. Adverse events were minimal and comparable between groups. This is the landmark study, and its 27.9% cortisol figure remains the most-cited specific number in the entire category.
A double-blind, randomised, placebo-controlled study in 60 healthy adults, designed specifically to compare 250mg/day (125mg twice daily) versus 600mg/day (300mg twice daily) versus placebo over 8 weeks. The critical finding: both doses produced significant reductions in stress, anxiety, and serum cortisol levels compared to placebo. The 600mg group showed greater magnitude of effect, establishing the dose-response relationship that underpins the clinical recommendation of 600mg/day as the optimal dose. This study is cited in the Elysium formulation rationale for the 600mg KSM-66® dose used in our KSM-66® Ashwagandha and underpins our Ashwagandha Dosage guide.
A 60-day RCT in 60 adults using 240mg/day of Shoden ashwagandha (a root-and-leaf extract standardised to 35% withanolide glycosides). The study found significant reductions in morning cortisol (p<0.001) and DHEA-S levels compared to placebo, with improvements on the Hamilton Anxiety Rating Scale (HAM-A). This study is important context: it demonstrates that extract quality and withanolide content determine efficacy, not raw milligrams alone. The 240mg dose of Shoden delivered approximately 84mg of withanolide glycosides — comparable to the withanolide content of a 600mg dose of KSM-66®.
A 10-week RCT in 60 adults with insomnia, using 300mg of KSM-66® twice daily. The study found significant improvements in sleep quality parameters (Pittsburgh Sleep Quality Index, Actigraphy), anxiety, and morning cortisol levels. This is clinically relevant to the cortisol-sleep bidirectional relationship: elevated evening cortisol is a primary driver of sleep onset difficulty, and the cortisol-lowering effect of ashwagandha appears to be part of the mechanism for its documented sleep benefits. We expand on this connection in Ashwagandha for Sleep.
A 60-day study examining three doses of Sensoril ashwagandha (root-and-leaf extract) — 125mg, 250mg, and 500mg/day — in 98 adults with chronic stress. All three doses produced significant cortisol reduction compared to placebo, with a clear dose-dependent effect. The 500mg/day group demonstrated the greatest reduction in cortisol. This trial established the cortisol-modulating dose range that subsequent RCTs have broadly validated, and is one of the earliest studies confirming dose-response.
An 8-week RCT in 52 chronically stressed adults receiving 300mg of ashwagandha root extract twice daily. The study found significant reductions in body weight, body mass index, food cravings, and serum cortisol — providing one of the clearer demonstrations of the metabolic consequences of cortisol modulation. We cover the cortisol-weight relationship in detail in our Ashwagandha for Weight Loss reference.
Published in Nutrients in January 2026, this is the most recent published RCT in the field. A randomised, double-blind, placebo-controlled trial involving 56 sub-elite team-sport athletes (rugby, water polo, and football) from Barcelona, with researchers from Leiden University and the University of Chichester (UK). Participants received 600mg/day of KSM-66® or placebo for 42 days during pre-season training. In female athletes, cortisol increased significantly in the placebo group during pre-season stress but showed no significant increase in the ashwagandha group — demonstrating a cortisol-stabilising effect under physiological stress. Male athletes showed attenuated cortisone (a cortisol metabolite) elevation. The study also found improved recovery perception in females and enhanced power output in males. This is the first ashwagandha trial conducted with partial UK institutional involvement (University of Chichester), and its sex-specific findings are novel to the field.
This systematic review and meta-analysis analysed 7 RCTs on cortisol outcomes (n=488) and 6 RCTs on perceived stress (n=488). The cortisol finding: significant reduction of −1.16 µg/dL (95% CI: −1.64 to −0.69, p<0.001). The perceived stress finding: no statistically significant improvement (SMD = −0.355, p=0.40). This is the finding that most supplement content ignores entirely. We address it directly in the section below.
Published in BJPsych Open in June 2025, this meta-analysis included 15 RCTs with a combined sample size of 873 participants. It found significant reductions in anxiety compared to placebo on the Hamilton Anxiety Rating Scale both at baseline and at 8 weeks. It also found significant cortisol reductions at 8 weeks. This is the largest and most recent meta-analysis in the field and represents the current best evidence synthesis. Critically, it accounts for heterogeneity in extract type and dose, and confirms the consistency of the cortisol finding across diverse trial populations.
An earlier systematic review and meta-analysis of 12 RCTs examining ashwagandha for stress and anxiety. The pooled effect for anxiety reduction was robust and statistically significant. Cortisol outcomes were similarly favourable. This study laid the methodological groundwork for the later Bachour and Albalawi meta-analyses.
A randomised, placebo-controlled safety study in healthy volunteers in Lucknow, India, using 600mg/day of KSM-66® for 8 weeks. The study confirmed safety and tolerability with no significant changes in haematological, hepatic, or thyroid parameters. This trial is frequently cited in the safety literature and supports the standard dose recommendation.
Published in Phytotherapy Research in October 2025, this is the first prospective, multi-centre, observational study to evaluate KSM-66® and other standardised ashwagandha root extracts over 12 months of continuous use. 191 adults aged 18–65 received 300mg twice daily for 12 months. Adverse events were mild and self-limiting in 9.4% of participants — nausea, sleeplessness, stomach discomfort — and resolved without intervention. No clinically significant changes in hepatic, renal, or thyroid function. We cover the safety implications in detail in Ashwagandha and Cortisol (existing companion article) and below.
A systematic review and meta-analysis examining ashwagandha's effects on sleep across multiple RCTs. The pooled effect demonstrated significant improvement in sleep quality parameters, with stronger effects in participants with diagnosed insomnia and at doses of 600mg/day. This study is foundational to the sleep-cortisol connection we expand on in Best Supplements for Sleep UK.
An earlier but well-cited systematic review concluding that ashwagandha demonstrates significant anxiolytic effects compared to placebo across multiple RCTs. This is the study often referenced in textbooks and is one of the earliest credible syntheses of the evidence.
A study on stress-related male infertility demonstrating that ashwagandha supplementation reduced cortisol and improved semen quality. This trial is relevant to the bidirectional relationship between cortisol and reproductive hormones and informs our coverage of Ashwagandha and Testosterone.
A 2026 prospective non-comparative study published in Frontiers in Nutrition further confirming the safety and tolerability of ashwagandha root extract in healthy adults. The study reinforces the conclusions of the Salve 2025 12-month dataset.
The Albalawi 2025 meta-analysis contains a finding that deserves direct attention: ashwagandha significantly reduces serum cortisol (biological marker) but does not significantly reduce perceived stress scores (psychological self-report). These two findings appear contradictory but are not, and understanding why is clinically meaningful for any UK consumer making a supplementation decision.
Cortisol is a hormone. It is measurable in blood, urine, and saliva with biochemical precision. Its reduction following ashwagandha supplementation is consistent, reproducible, and statistically significant across multiple independent trials and meta-analyses. This finding is not in serious scientific question.
Perceived stress is a subjective self-report. The Perceived Stress Scale (PSS) measures how overwhelmed, uncontrollable, and unpredictable people feel their life circumstances to be. It is influenced by life events, cognitive appraisal, coping resources, social support, financial pressure, sleep quality, relationship dynamics, and a hundred other variables that a 600mg capsule does not touch.
The implication is not that ashwagandha does not work. The implication is that lowering cortisol is a necessary but not always sufficient condition for resolving the subjective experience of chronic stress. If the stressor itself is unresolved — the job is still overwhelming, the financial pressure remains, the relationship is broken, the workload has not changed — then cortisol reduction alone will not make those circumstances feel manageable. The biology shifts; the cognitive appraisal of the life situation does not, automatically.
This is honest, and it matters for UK consumers making supplementation decisions. Ashwagandha is not a therapeutic replacement for behavioural change, CBT, improved sleep hygiene, or addressing the structural causes of chronic stress. It is a validated biological intervention for the hormonal component of the stress response — and it does that job well. Used in combination with the other elements (sleep restoration, dietary improvement, stress management, where appropriate professional support), the effect is genuinely compounded.
The studies that do show significant improvements in perceived stress alongside cortisol reduction (Chandrasekhar 2012, Salve 2019, Langade 2019) typically recruit specifically stressed populations and use higher doses (600mg/day). The meta-analytic result masks heterogeneity: some populations respond strongly across both biological and psychological markers; others see primarily biochemical benefit. This is consistent with the broader research on adaptogenic compounds.
Our recommendation: treat cortisol reduction as the primary, measurable outcome. If perceived stress improves alongside it — which it does in many individuals, particularly those whose stress is primarily driven by physiological HPA dysregulation rather than unresolved circumstantial factors — that is a secondary benefit. But we will not promise what the evidence does not guarantee. For broader stress strategy beyond ashwagandha alone, see our Best Supplements for Stress UK guide.
The single most important purchasing decision in the ashwagandha category is not dose — it is extract quality and standardisation. The clinical evidence for cortisol reduction is almost entirely generated using proprietary standardised extracts: KSM-66® (Ixoreal Biomed, root-only, ≥5% withanolides by HPLC), Sensoril® (root and leaf, ≥10% withanolide glycosides), and Shoden® (root and leaf, 35% withanolide glycosides). Non-standardised ashwagandha root powder — which constitutes the majority of cheap supplement products — has no consistent withanolide content and therefore no predictable dose-response relationship.
For a detailed comparison of extract types versus raw root powder, see our Ashwagandha Extract vs Root Powder reference. For the specific case for KSM-66® as the gold-standard extract, see our KSM-66® Ashwagandha Review.
Standardisation means a guarantee that every capsule contains a verified minimum concentration of the active compound — withanolides, in the case of ashwagandha — confirmed by HPLC (High-Performance Liquid Chromatography) analysis on every production batch. KSM-66® is standardised to ≥5% withanolides, root-only, with the certificate of analysis available on the Ixoreal Biomed website. This is what allows clinical trial findings to translate to consumer products: the supplement on the shelf contains the same active compound profile that produced the results in the published research.
Elysium Ashwagandha contains 600mg of KSM-66® per capsule — the precise dose validated in Chandrasekhar et al. (2012), Salve et al. (2019), and the 2026 Gonzalez-Blanch athlete RCT. Our KSM-66® Ashwagandha uses root-only extract (the traditional therapeutic component in Ayurvedic practice and the form used in the majority of clinical research), manufactured to UK GMP standards.
"1,500mg of ashwagandha per serving" — typically generic root powder, no extract type stated, no withanolide standardisation specified.
"600mg KSM-66® root extract, standardised to ≥5% withanolides by HPLC."
A significant proportion of UK ashwagandha supplements sell tablets containing 1,500mg of ashwagandha root powder. This sounds like a generous dose. In practice, ashwagandha root powder contains approximately 1–5% withanolides depending on growing conditions, part of plant, and processing — meaning 1,500mg of root powder delivers approximately 15–75mg of withanolides. At the lower end, this is less than half the withanolide content of 600mg of KSM-66® (which is standardised to ≥5%, delivering ≥30mg of guaranteed withanolides). More importantly, the total withanolide content of generic root powder cannot be verified by the consumer from the label because the supplement is not standardised to a specific percentage.
This is the single most common mistake we see UK buyers make in this category. The 1,500mg figure is marketing — it is the weight of the raw material, not a measure of clinical efficacy. The 600mg figure on a KSM-66® product is the dose used in the trials that generated the cortisol reduction findings. They are not comparable units. For a comprehensive comparison of UK ashwagandha products against extract quality criteria, our Best Ashwagandha UK guide is the most relevant resource.
The clinical literature does not support a one-size-fits-all dose. Different outcomes have different optimal dose ranges based on the available RCT data. For the full dosing framework across all use cases, our Ashwagandha Dosage guide is the most comprehensive resource.
| Goal | Recommended dose | Evidence source | Duration to effect | Notes |
|---|---|---|---|---|
| Cortisol reduction (primary) | 600mg/day KSM-66® | Chandrasekhar 2012; Salve 2019; Bachour 2025 | 8–12 weeks | Split as 300mg morning + 300mg evening for steady plasma levels |
| Stress & anxiety | 300–600mg/day | Salve 2019; Langade 2019; Bachour 2025 | 4–8 weeks | 600mg shows greater magnitude in dose-response trials |
| Sleep quality | 600mg/day (300mg × 2) | Langade 2019; Cheah 2021 | 4–6 weeks | Evening dose most important; reduces evening cortisol |
| Athletic cortisol stabilisation | 600mg/day | Gonzalez-Blanch 2026 | 4–6 weeks | Sex-specific benefits documented; take with dinner |
| Cortisol-driven weight management | 600mg/day | Choudhary 2017 | 8 weeks | Weight, BMI, and food cravings all reduced |
| Minimum effective dose | 250mg/day | Salve 2019; Auddy 2008 | 8 weeks | Measurable cortisol reduction but lower magnitude |
The question of timing matters because cortisol follows a diurnal rhythm. If the primary goal is overall cortisol reduction, twice-daily dosing (morning and evening) maintains the most consistent plasma concentration of withanolides and provides HPA modulation across both the morning cortisol awakening response and the evening decline. The Chandrasekhar 2012 trial used 300mg twice daily; Langade 2019 used 300mg twice daily. Both produced significant cortisol reductions.
The evidence slightly favours evening administration — reducing cortisol during the window when it should naturally be declining but often remains elevated in chronically stressed individuals. This supports sleep onset and restores normal diurnal rhythm more directly. Our KSM-66® Ashwagandha (600mg) delivers the full clinical dose in a single capsule, which can be taken in the evening with food, or split across morning and evening depending on preference.
All withanolide-based RCTs use oral capsules taken with food or water. The steroidal lactone structure of withanolides suggests some fat solubility, and taking ashwagandha with a meal containing some fat may improve absorption marginally. If you experience nausea on an empty stomach, switch to with-meal dosing — this is the standard clinical trial protocol and resolves most mild gastrointestinal complaints.
This is the framework we use at Elysium for clients beginning ashwagandha supplementation with cortisol modulation as the primary goal. It synthesises the dosing literature, the timing data, the timeline of effect, and the practical realities of building a daily protocol you will actually maintain for 12 weeks — which is the window in which the most consistent cortisol reductions are documented.
One of the most common sources of frustration with ashwagandha is misaligned expectations about onset. Unlike pharmaceutical anxiolytics or sedatives — which typically produce acute effects within hours — ashwagandha's cortisol-modulating effects emerge through gradual HPA axis recalibration. Most people do not notice a dramatic single-day change. They notice, over weeks, that they are sleeping better, waking with more energy, and responding to stress with less reactivity. The cortisol data confirms what subjective experience often reports: change is real but gradual.
| Timeframe | What may happen | What the evidence shows |
|---|---|---|
| Days 1–7 | Possibly no subjective change; some report mild sedation | No significant cortisol changes expected — plasma accumulation beginning |
| Weeks 2–3 | Some report improved sleep onset; reduced evening anxiousness | Withanolides accumulate; early HPA modulation beginning |
| Weeks 4–5 | Improved sleep quality most commonly reported first | Langade 2019 showed significant sleep improvements beginning here |
| Weeks 6–8 | Measurable cortisol reduction; perceived stress improvements emerge | Chandrasekhar 2012 and Salve 2019 both measured at 56–60 days |
| Weeks 8–12 | Full cortisol reduction achieved; HPA rhythm normalising | Greatest magnitude of effect at 8–12 weeks across the literature |
A note on the cortisol trajectory in the Gonzalez-Blanch 2026 athlete study is worth adding: the researchers found that KSM-66® did not so much reduce resting cortisol as prevent the cortisol increase that occurred in the placebo group under the physiological stress of pre-season training. This cortisol-stabilising mechanism — preventing dysregulation that stress would otherwise produce — may be as clinically relevant as direct reduction, particularly for individuals whose cortisol is currently at the upper end of normal range rather than clinically elevated.
Serum cortisol testing is available in the UK through private clinics (typically £40–80 for a morning cortisol blood draw) and is worth considering if you want objective confirmation of response. Most people, however, track ashwagandha's effects subjectively, and doing so systematically produces more useful information than a general impression of "feeling better" or "not noticing anything." The five markers below correspond directly to the downstream effects of cortisol on physiology and behaviour documented across the clinical literature.
Track these five markers in a notes app or a simple weekly grid. After 8 weeks, review the trajectory rather than individual days. Progress in ashwagandha is non-linear — a difficult week at work will affect all five scores. What matters is the baseline trend across the 8-week window. For broader self-monitoring frameworks across the supplement category, see our How to Read Supplement Labels UK reference.
Safety data for ashwagandha was, until recently, limited to trials of 8–12 weeks in duration. The field's most significant gap was addressed by Salve, Kale, Prajapati et al. (2025) in a paper published in Phytotherapy Research in October 2025: the first prospective, multi-centre, observational study evaluating KSM-66® and other standardised ashwagandha root extracts over 12 months of continuous use.
The study enrolled 191 adults aged 18–65. Clinical assessments were conducted at baseline and monthly for 12 months; laboratory assessments (hepatic, renal, thyroid function panels) at baseline, 6 months, and 12 months. The primary outcome was adverse events. The key findings:
The study's lead author, Kartikeya Baldwa, CEO of Ixoreal Biomed, described it as "a pivotal milestone for the ashwagandha industry" — the first time the field had comprehensive long-term safety evaluation across duration, dose, and scale. For UK consumers considering ashwagandha as a daily supplement, the 12-month safety data is materially reassuring, and represents a meaningful advance over the short-duration safety window that characterised the evidence base until 2025.
Ashwagandha should be used with caution by individuals with pre-existing thyroid conditions (the herb has been shown to elevate thyroid hormones in hypothyroid contexts and is contraindicated in hyperthyroidism). It is not recommended during pregnancy or breastfeeding based on current evidence. A 2026 case report documented adrenal insufficiency in a patient taking approximately 950mg/day for one year — above the clinical dose range. Individuals with autoimmune conditions, or those taking immunosuppressants, should consult a GP or pharmacist before use. The clinical dose range of 300–600mg/day of a standardised extract has the strongest safety record in the available literature.
Across the 12-month Salve 2025 study and the broader RCT literature, mild side effects occur in approximately 9–11% of users. The most common are nausea (usually resolved by taking with food), mild gastrointestinal upset, drowsiness (often desirable in the evening, less so in the morning), and headache. These typically resolve within the first 1–2 weeks of supplementation or with adjustment of dose timing.
Multiple case reports have documented ashwagandha-associated liver injury — typically presenting as jaundice and elevated liver enzymes, appearing 2–12 weeks after starting supplementation, and resolving after discontinuation. These cases are rare relative to global ashwagandha use, and the causal relationship in most reports is probable rather than confirmed (patients may have been taking additional supplements or medications). Nonetheless, this is a real signal that the Salve 2025 12-month safety study specifically sought to characterise at scale — and found no evidence of clinically significant hepatic changes in 191 participants at standard doses. The signal is worth awareness rather than alarm, and is proportionate to the risk profile of many widely-used over-the-counter supplements. If you develop signs of liver problems — jaundice, dark urine, persistent abdominal pain — discontinue and seek medical advice promptly.
Ashwagandha has been shown to elevate thyroid hormones in hypothyroid contexts — which can be therapeutically useful in some clinical settings but is a clear contraindication in hyperthyroidism and in patients on levothyroxine therapy without medical supervision. The Brendler 2025 endocrine review is the most comprehensive synthesis of the hormonal effects.
Ashwagandha has documented or theoretical interactions with several drug classes. While not exhaustive, the following warrant attention before starting supplementation:
This is not a complete list. If you take prescription medication, consult your GP or pharmacist before starting ashwagandha. For broader UK supplement safety regulation, see UK Supplement Regulations Guide.
In the United Kingdom, ashwagandha is classified as a food supplement under the Food Supplements (England) Regulations 2003 and equivalent devolved regulations. It is not a licensed medicine and does not require MHRA approval for sale. This means that UK ashwagandha supplements cannot make medicinal claims — including direct claims that the product "lowers cortisol," "treats stress," or "reduces anxiety." These are medicinal claims that are legally reserved for licensed medicines.
What UK supplement labels can legitimately say is constrained by Food Standards Agency (FSA) and Advertising Standards Authority (ASA) guidance on health claims. Claims must be substantiated and not misleading. General wellness language — "supports the body's normal stress response," "contributes to normal psychological function" — is acceptable if substantiated. Direct claims about cortisol levels, clinical outcomes, or disease treatment are not.
This creates a peculiar situation for UK consumers: the scientific evidence for ashwagandha's cortisol-modulating effects is substantial, but supplement manufacturers cannot state it directly on packaging without risk of regulatory action. The solution is research literacy — reading the clinical evidence directly rather than relying on label language designed to navigate regulatory constraints. Our UK Supplement Regulations Guide covers the full framework.
Elysium Supplements is committed to clinical transparency: we publish the evidence behind every product, name the extracts we use (KSM-66®), state the dose (600mg), and cite the trials. This is the standard of evidence communication that the UK supplement industry should operate at, and we intend to hold ourselves to it even where regulatory constraints prevent us from summarising it on the label itself.
The combination of ashwagandha and magnesium glycinate addresses cortisol dysregulation through two complementary and non-overlapping mechanisms, and represents one of the most rational stacking decisions in the stress and sleep supplement category.
Ashwagandha modulates the HPA axis — reducing the hormonal signal that drives cortisol output. This is a top-down, neuroendocrine mechanism operating at the hypothalamic level. Magnesium glycinate addresses the downstream consequences of elevated cortisol on the central nervous system: cortisol depletes intracellular magnesium, and magnesium deficiency amplifies the stress response through NMDA receptor sensitisation and reduced GABAergic activity. Supplementing magnesium glycinate restores the cellular magnesium status that chronic cortisol exposure depletes, while also providing direct anxiolytic effects via GABA modulation that are independent of cortisol.
The practical result of combining the two: ashwagandha works on the hormonal driver; magnesium glycinate addresses the neurological consequences of that driver having been active for months or years. The HPA calms from above; the nervous system calms from below. Most people who add magnesium glycinate to an ashwagandha regimen report faster onset of sleep improvement than either supplement produces alone — a finding that is mechanistically coherent with the dual-pathway model.
For comprehensive coverage of magnesium glycinate's mechanisms and dosing, see Magnesium Glycinate Benefits, Magnesium Glycinate for Sleep, and Magnesium Glycinate for Anxiety. For the specific magnesium-cortisol relationship, our Magnesium and Cortisol guide is the deepest resource. For the broader UK magnesium category and how to evaluate UK products, see Best Magnesium for Sleep UK, Magnesium for Stress UK, and Magnesium for Anxiety UK.
The second clinically rational stack pairs ashwagandha with Lion's Mane (Hericium erinaceus) — addressing both the hormonal stress component (ashwagandha) and the cognitive performance component (Lion's Mane) that chronic stress so often degrades. Lion's Mane's hericenones and erinacines have been shown to support nerve growth factor (NGF) synthesis and may support cognitive function and focus through a mechanism entirely independent of the HPA axis.
Our Stress & Focus Stack pairs 600mg KSM-66® Ashwagandha with our Lion's Mane formulation in a single subscription — the most popular bundle for adults managing both stress and cognitive demand. For the deeper question of whether the two can be safely combined, see Ashwagandha and Lion's Mane Together. For broader Lion's Mane context, our Lion's Mane product page and the Lion's Mane Benefits guide are the primary resources, with deeper material at Lion's Mane for Focus and Lion's Mane for Memory.
Sleep and cortisol exist in a bidirectional relationship that can become a destructive feedback loop. Elevated evening cortisol disrupts sleep onset and quality; poor sleep elevates the next day's cortisol output; the cycle compounds across weeks. Breaking the loop typically requires intervention at multiple points: behavioural sleep hygiene, environmental factors, and — where the cortisol driver is dominant — pharmacological or nutraceutical intervention.
The Langade 2019 RCT directly demonstrated that 600mg/day of KSM-66® significantly improved Pittsburgh Sleep Quality Index scores alongside cortisol reduction in adults with insomnia. The Cheah 2021 meta-analysis pooled multiple sleep trials and confirmed the sleep effect at the meta-analytic level. The mechanism appears to be primarily through reduction of evening cortisol elevation rather than direct sedation. For broader UK sleep supplementation strategy, see Best Supplements for Sleep UK, Natural Sleep Aids UK, and Cortisol and Sleep.
The anxiolytic effect of ashwagandha is among the most robustly documented in the supplement category. The Bachour 2025 meta-analysis found significant reductions in Hamilton Anxiety Rating Scale (HAM-A) scores at 8 weeks in adults with stress and anxiety. The mechanism appears multifactorial: cortisol reduction (which itself reduces anxiety-driving hyperarousal), modulation of GABAergic activity, and possible effects on serotonergic and dopaminergic systems.
The anxiety effect is large enough that the World Federation of Societies of Biological Psychiatry (WFSBP) and the Canadian Network for Mood and Anxiety Treatments (CANMAT) provisionally recommend ashwagandha for generalized anxiety disorder — a meaningful endorsement from medical bodies that do not endorse herbal interventions lightly. For dedicated coverage, see Ashwagandha for Anxiety and the broader Best Supplements for Anxiety UK guide.
Chronic cortisol elevation has well-documented metabolic consequences: increased visceral fat deposition, insulin resistance, food cravings (particularly for high-calorie, high-carbohydrate foods), and altered glucose metabolism. The Choudhary 2017 RCT specifically examined whether reducing cortisol via ashwagandha would have downstream metabolic effects, and found significant reductions in body weight, BMI, and food cravings alongside the cortisol effect.
This does not make ashwagandha a weight loss supplement. It modulates one of the hormonal drivers of stress-related weight gain — relevant for adults whose weight changes appear to track with stress levels rather than calorie intake alone. Our Ashwagandha for Weight Loss reference covers the full evidence and addresses common misconceptions.
Ashwagandha's effects on testosterone in men have been documented in several RCTs (notably Mahdi et al., 2011 in stress-related infertility, and subsequent confirmatory trials). The effect is mechanistically coherent with cortisol reduction: cortisol and testosterone exist in an inverse relationship, and reducing chronically elevated cortisol typically allows testosterone to rise toward the upper end of an individual's normal range. The Gonzalez-Blanch 2026 athlete study, however, found no significant testosterone change in a healthy athletic population — suggesting the testosterone effect is most pronounced in stressed or stress-induced low-testosterone populations.
For a deeper exploration of this relationship, see Ashwagandha and Testosterone and Ashwagandha Benefits for Men.
The Gonzalez-Blanch 2026 athlete RCT is the first study to systematically stratify ashwagandha's cortisol effects by sex. In female athletes under pre-season training stress, KSM-66® prevented the cortisol elevation that occurred in the placebo group. In male athletes, it attenuated cortisone elevation and enhanced power output. Both effects represent meaningful HPA modulation but the precise hormonal profile differs by sex.
For women specifically, ashwagandha is also relevant beyond the cortisol axis — there is evidence for benefit in stress-related menstrual cycle disruption and perimenopausal stress responses. See Ashwagandha Benefits for Women for the full picture. For broader cortisol-driven supplementation in women's hormonal health, our Supplements for Hormone Balance UK guide is relevant.
We hold our own products to the same audit framework we apply to competitor analysis. The Elysium Ashwagandha audit score of 75/80 reflects the following:
The two points deducted in the audit reflect areas of continued investment: full public publication of every batch certificate of analysis (currently available on request rather than published; a 2026 roadmap item) and further investment in independent third-party validation beyond the Ixoreal Biomed standardisation guarantee. We treat the audit as a living standard.
To explore the full Elysium product range, see Elysium KSM-66® Ashwagandha, the Stress & Focus Stack, and our Complete Wellness System.
Root-only extract, standardised to ≥5% withanolides by HPLC. UK GMP manufactured. No proprietary blends, no inflated powder doses. Formulated on the Chandrasekhar 2012 evidence base.
View KSM-66® Ashwagandha
Lion's Mane and Ashwagandha. Together, by design.
SHOP THE STRESS & FOCUS STACK
